Abbott India gained sharply on Indian bourses after the company announced plans to amalgamate the operations of Solvay Pharma India with itself.
Abbott India gained sharply on Indian bourses after the company announced plans to amalgamate the operations of Solvay Pharma India with itself.
Shares of Abbott India rose by 3.3% to touch Rs1,472.75 ($32.40) on 24 November after the company said that its...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
